117 related articles for article (PubMed ID: 7721546)
1. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
[TBL] [Abstract][Full Text] [Related]
2. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
Runge VM; Lee C; Iten AL; Williams NM
Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
[TBL] [Abstract][Full Text] [Related]
4. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
[TBL] [Abstract][Full Text] [Related]
5. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
[TBL] [Abstract][Full Text] [Related]
6. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
[TBL] [Abstract][Full Text] [Related]
7. High-dose gadoteridol in MR imaging of intracranial neoplasms.
Runge VM; Kirsch JE; Burke VJ; Price AC; Nelson KL; Thomas GS; Dean BL; Lee C
J Magn Reson Imaging; 1992; 2(1):9-18. PubMed ID: 1623287
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
Runge VM
Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
[TBL] [Abstract][Full Text] [Related]
12. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
14. Detectability of early brain meningitis with magnetic resonance imaging.
Runge VM; Wells JW; Williams NM; Lee C; Timoney JF; Young AB
Invest Radiol; 1995 Aug; 30(8):484-95. PubMed ID: 8557515
[TBL] [Abstract][Full Text] [Related]
15. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
[TBL] [Abstract][Full Text] [Related]
16. High-dose applications of gadolinium chelates in magnetic resonance imaging.
Runge VM; Kirsch JE; Thomas GS
Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
Runge VM; Kirsch JE; Wells JW; Woolfolk CE
AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis.
Runge VM; Williams NM
Invest Radiol; 1998 Jan; 33(1):45-50. PubMed ID: 9438509
[TBL] [Abstract][Full Text] [Related]
20. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.
Runge VM; Wells JW; Nelson KL; Linville PM
J Magn Reson Imaging; 1994; 4(5):669-73. PubMed ID: 7981511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
